Altundag K et al. Monoclonal antibody-based targeted therapy in breast cancer. Curr Med Chem Anti-Canc Agents 2005;5(2):99-106. Abstract

Arpino G et al. Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition. Breast Cancer Res Treat 2004;Abstract 23.

Arteaga CL et al. ECOG1100: A phase I-II study of combined blockade of the erbB receptor network with trastuzumab and gefitinib (Iressa) in patients (pts) with HER2-overexpressing metastatic breast cancer (met br ca). Breast Cancer Res Treat 2004;Abstract 25.

Baselga J et al. Updated efficacy and safety analyses of 3-weekly Herceptin monotherapy in women with HER2-positive metastatic breast cancer: Results from twelve months of followup to a phase II study. Breast Cancer Res Treat 2004;Abstract 3042.

Bayo-Calero JL et al. A multicenter study with trastuzumab and vinorelbine as first and 2nd line treatment in patients (pats) with Her2 positive metastatic breast cancer (MBC). Breast Cancer Res Treat 2004;Abstract 5069.

Brufsky A et al. Phase II study of gemcitabine (Gem) and trastuzumab (T) combination therapy in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC). First stage results. Breast Cancer Res Treat 2004;Abstract 3047.

Burris H 3rd et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004;22(9):1621-9. Abstract

Burris III HA et al. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. Breast Cancer Res Treat 2004;Abstract 3043.

Burstein HJ et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study. J Clin Oncol 2003;21(1):46- 53. Abstract

Burstein HJ et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21(15):2889-95. Abstract

Buzdar AU et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005 Feb 28; [Epub ahead of print]. Abstract

Fornier MN et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: Association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 2005;16(2):234-9. Abstract

Geyer CE Jr et al. Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of Adriamycin and cyclophosphamide (AC) followed by Taxol to that of AC followed by Taxol plus Herceptin in patients (Pts) with operable, nodepositive (N+), HER-2 overexpressing breast cancer (HER2+BC). Breast Cancer Res Treat 2003;Abstract 23.

Kostler WJ et al. Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: A single-institution experience. Anticancer Drugs 2005;16(2):185-90. Abstract

Leyland-Jones B et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003;21(21):3965-71. Abstract

Mehta RS et al. High pathological complete remission rate following neoadjuvant taxane, carboplatin and trastuzumab therapy after doxorubicin and cyclophosphamide in Her-2 positive breast cancer patients. Breast Cancer Res Treat 2004;Abstract 1110.

Montemurro F et al. A phase II study of threeweekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 2004;66(1):38-45. Abstract

Okawa Y et al. Successful combination therapy with trastuzumab and paclitaxel for adriamycinand docetaxel-resistant inflammatory breast cancer. Breast Cancer 2004;11(3):309-12. Abstract

Pegram MD et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2- positive advanced breast cancer. J Natl Cancer Inst 2004;96(10):759-69. Abstract

Perez EA et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the north central cancer treatment group n9831 intergroup adjuvant trial. J Clin Oncol 2004;22(18):3700-4. Abstract

Reddy JC et al. Outcome of patients treated with docetaxel versus paclitaxel in a non-randomized phase IV trial of first-line taxane/trastuzumab therapy in patients with HER2+ metastatic breast cancer (MBC). Breast Cancer Res Treat 2004;Abstract 3050.

Risio M et al. HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment. Oncol Rep 2005;13(2):305-9. Abstract

Robert NJ et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival. Proc ASCO 2004;Abstract 573.

Rugo HS et al. registHER: Results from a prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer. Breast Cancer Res Treat 2004; Abstract 2042.

Sanchez-Rovira P et al. Neoadjuvant chemotherapy with a dose-dense and sequential combination of epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine + trastuzumab in stage II and III breast cancer. A phase II and pharmacogenomic study. Breast Cancer Res Treat 2004;Abstract 2095.

Seidman A et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20(5):1215-21. Abstract

Seidman AD et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc ASCO 2004;Abstract 512.

Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract

Spector N et al. The ErbB2 pathway in breast cancer: Best approaches for maximum efficacy. Breast Cancer Res Treat 2004;Abstract MS3-4.

Stewart JA et al. Standardized echocardiographic monitoring in a trial of trastuzumab plus a taxane administered every 3 weeks as first-line therapy for HER2+ metastatic breast cancer (MBC) detects a low rate of asymptomatic cardiac dysfunction. Breast Cancer Res Treat 2004;Abstract 3052.

Tedesco KL et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization- positive metastatic breast cancer: A multi-institutional phase II trial. J Clin Oncol 2004;22(6):1071-7. Abstract

Tripathy D et al. Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2004;5(4):293-8. Abstract

Tripathy D et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22(6):1063-70. Abstract

Tusquets I et al. Study of docetaxel (T) and trastuzumab (H) combination, administered every 21 days, in patients (p) with metastatic breast cancer (MBC) and HER-2 over-expression. Breast Cancer Res Treat 2004;Abstract 3054.

Valero V et al. Normal cardiac biopsy results following co-administration of doxorubicin (A), cyclophosphamide (C) and trastuzumab (H) to women with HER2 positive metastatic breast cancer. Proc ASCO 2004;Abstract 572.

Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract

Vogel CL, Franco SX. Clinical experience with trastuzumab (Herceptin). Breast J 2003;9(6):452- 62. Abstract

Wolff AC et al. Cardiac safety and clinical activity of pegylated liposomal doxorubicin (D) and docetaxel (T) with and without trastuzumab (H) as 1st line chemotherapy in HER2-positive and HER2-negative metastatic breast cancer (MBC): Eastern Cooperative Oncology Group (ECOG) trial E3198. Breast Cancer Res Treat 2004;Abstract 3040.

Xu L et al. Results of a phase II trial of Herceptin plus Xeloda in patients with previously untreated HER2-positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2004;Abstract 3049